Log In
Print
BCIQ
Print
Print this Print this
 

Sirukumab (CNTO 136)

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionHuman IgG1 kappa mAb against IL-6
Molecular Target Interleukin-6 (IL-6)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today